SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-211456
Filing Date
2023-08-14
Accepted
2023-08-14 07:29:57
Documents
17
Period of Report
2023-08-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d497848d8k.htm   iXBRL 8-K 40166
2 EX-4.1 d497848dex41.htm EX-4.1 87046
3 EX-10.1 d497848dex101.htm EX-10.1 208002
4 EX-99.1 d497848dex991.htm EX-99.1 79488
5 EX-99.2 d497848dex992.htm EX-99.2 10480
9 GRAPHIC g497848g0812092036694.jpg GRAPHIC 3275
  Complete submission text file 0001193125-23-211456.txt   662023

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230814.xsd EX-101.SCH 2845
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230814_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230814_pre.xml EX-101.PRE 11704
11 EXTRACTED XBRL INSTANCE DOCUMENT d497848d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 231166256
SIC: 2836 Biological Products, (No Diagnostic Substances)